Frazier Life Sciences has raised more than $1.1 billion for its long-running public biotech fund, adding fresh capital to a vehicle the Palo Alto-based firm launched in 2021. According to the company, the fund has now raised $2.8 billion in total.
The strategy is focused on long-term investments in small- and mid-cap public biotech companies, with the option to deploy capital into later-stage private companies through crossover financings. That matters in a market where many biotechs still need specialist investors that can move across private and public settings rather than fund only one side of the market.
Where The Fund Is Pointed
Frazier said several of the fund’s largest positions over the past five years ended up as acquisition targets. The examples it named were Verona Pharma, which Merck & Co. acquired for $10 billion in 2025, and Alpine Immune, which Vertex Pharmaceuticals bought for $4.9 billion in 2024.
Those examples give a clearer read on how the firm is framing the opportunity set: not broad exposure to the whole biotech market, but concentrated bets on companies that can create enough clinical or commercial value to attract strategic buyers. In that sense, the raise is also a vote that acquisition-driven exits remain an important part of the public biotech investing case.
Albert Cha, M.D., Ph.D., managing partner at Frazier Life Sciences, said the firm sees continued momentum from promising clinical trials, FDA approvals and successful commercial launches within and outside its portfolio. Jamie Brush, M.D., general partner and portfolio manager at FLS, said the firm hopes to support development across a wide spectrum of diseases with the backing of its limited partners.
The Broader Capital Picture
The public fund is only one piece of Frazier’s capital base. Since 2016, the firm has also raised more than $3.6 billion across five dedicated venture funds focused on private early-stage biotechs, including $1.3 billion raised last year. In total, FLS said it manages over $6.9 billion in capital across its venture and public funds.
The firm also said that more than 50 FLS portfolio companies have completed IPOs or been acquired since 2015. That record helps explain why a manager with an established biotech brand can still gather large pools of capital even when the wider market is inconsistent.
The timing is notable. Fierce Biotech said Luma Group closed its inaugural life sciences venture capital fund at $410 million yesterday, and its fundraising tracker counted nine biotechs that raised a combined total of nearly $1 billion in the first 10 days of September. The signal from Frazier’s raise is less that money is flowing everywhere than that experienced sector investors are still attracting large commitments to target companies they believe can produce clinical milestones, approvals or M&A outcomes.
